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Purpose: The objectives of this research were to assess the biocompatibility of self-assembled 
Fe3O4 magnetic nanoparticles (MNPs) loaded with daunorubicin (DNR), ie, (Fe3O4-MNPs/DNR), 
and to explore their potential application in the treatment of hematologic malignancies.
Methods: A hemolysis test was carried out to estimate the hematologic toxicity of Fe3O4-
MNPs/DNR and a micronucleus assay was undertaken to identify its genotoxicity. Fe3O4-MNPs/
DNR were injected intraperitoneally into mice to calculate the median lethal dose (LD50). The 
general condition of the mice was recorded, along with testing for acute toxicity to the liver 
and kidneys.
Results: Hemolysis rates were 2.908%, 2.530%, and 2.415% after treatment with different 
concentrations of Fe3O4-MNPs/DNR. In the micronucleus assay, there was no significant 
  difference in micronucleus formation rate between the experimental Fe3O4-MNPs/DNR 
groups and negative controls (P . 0.05), but there was a significant difference between the 
experimental groups and the positive controls (P , 0.05). The LD50 of the Fe3O4-MNPs/DNR 
was 1009.71 mg/kg and the 95% confidence interval (CI) was 769.11–1262.40 mg/kg, while that 
of the DNR groups was 8.51 mg/kg (95% CI: 6.48–10.37 mg/kg), suggesting that these nano-
particles have a wide safety margin. Acute toxicity testing showed no significant difference in 
body weight between the treatment groups at 24, 48, and 72 hours after intraperitoneal injection. 
The mice were all in good condition, with normal consumption of water and food, and their 
stools were formed and yellowish-brown. Interestingly, no toxic reactions, including instability 
of gait,   convulsion, paralysis, and respiratory depression, were observed. Furthermore, alanine 
transaminase, blood urea nitrogen, and creatinine clearance in the experimental Fe3O4-MNPs/
DNR groups were 66.0 ± 28.55 U/L, 9.06 ± 1.05 mmol/L, and 18.03 ± 1.84 µmol/L, respectively, 
which was not significantly different compared with the control and isodose DNR groups.
Conclusion: Self-assembled Fe3O4-MNPs/DNR appear to be highly biocompatible and safe 
nanoparticles, and may be suitable for further application in the treatment of hematologic 
malignancies.
Keywords: magnetic nanoparticles, Fe3O4, daunorubicin, biocompatibility, hematologic 
malignancies, therapy
Introduction
Magnetic nanoparticles (MNPs) have been investigated for various biomedical 
applications, including targeted therapy,1,2 magnetic hyperthermia,3 and contrast 
enhancement in magnetic resonance imaging.4 The ability to transport anti-
cancer drugs via MNPs to specific parts of the body reduces the side effects of 
  chemotherapy. Our earlier research has shown that magnetic Fe3O4 nanoparticles International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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(Fe3O4-MNPs) combined with daunorubicin (DNR) and 
5-bromotetrandrine are able to overcome multidrug 
resistance in hematologic malignancies, and achieve a 
satisfactory therapeutic effect, without histologic   toxicity to 
nontarget organs or tissues.5–7 On the other hand, simultane-
ous use of hyperthermia and low-doses of chemotherapeutic 
agents decreases tumor growth through targeted cytotoxic-
ity and reduces systemic side effects.8 Therefore, MNPs are 
expected to enhance therapeutic effects and to reduce side 
effects when used in combination with conventional cancer 
treatment. On this basis, we prepared Fe3O4-MNPs loaded 
with DNR (Fe3O4-MNPs/DNR) as a novel therapeutic agent 
using chemical coprecipitation and emulsification under 
ultrasound guidance. It is essential to determine the bio-
compatibility for in vivo biomedical   applications to ensure 
their safe clinical use,9 and the   constructed nanoparticles 
must have low toxicity and little innate bioreactivity. In 
this research, we evaluated the biocompatibility and sta-
bility of self-assembled Fe3O4-MNPs/DNR by hemolysis 
testing, micronucleus assay, and detection of median lethal 
dose (LD50).
Materials and methods
experimental agents
Ferric chloride, ferrous sulfate, and ammonia water were 
obtained from Hanguang Chemical Reagent Co, Ltd 
(Shanghai, China). Albumin was prepared from human 
plasma obtained from Shanghai RAAS Blood Products 
Co Ltd (Shanghai, China). Other reagents used included 
daunorubicin hydrochloride (Pharmacia Italia SpA, Milan, 
Italy), potassium oxalate (analytical grade; Shanghai First 
Reagent Factory, Shanghai, China), cyclophosphamide 
(Jiangsu Hengrui Medicine Co Ltd., Lianyungang, China) 
methanol (Sinopharm Chemical Reagent Co Ltd, Shanghai, 
China), Giemsa staining solution (Chroma, Bellows Falls, 
VT), 4,6-diamidino-2-phenylindole (DAPI) staining solution 
(Beyotime Institute of Biotechnology, Jiangsu, China), and 
a T6 ultraviolet-visible spectrophotometer (Beijing Purkinje 
General Instrument Co Ltd, Beijing, China).
experimental animals
Kunming mice, age-matched (six weeks of age) and weight-
matched (18–22 g), were purchased from the Shanghai 
National Center for Laboratory Animals. They were 
  maintained in clean facilities. After matching for gender, 
the mice were randomly assigned to treatment groups for 
experimental purposes.
Preparation of Fe3O4-MNPs-DNr
Fe3O4-MNPs were prepared by chemical coprecipitation,10 
and then Fe3O4-MNPs, DNR, and albumin were mixed in 
certain proportions with emulsification under ultrasonic 
guidance.11 After formation of the compound nanoparticles 
containing the DNR and magnetic materials, solidifying and 
drying through evaporation, the nanoparticles were preserved 
at 4°C. The materials were misced bene for 30 minutes in 
the presence of ultrasound. The effective drug-loading rate 
was 1%, as calculated by high-performance liquid chroma-
tography and using a fluorescence detector.
hemolysis test
Blood was obtained from healthy rabbits and anticoagulated 
with potassium oxalate, at a final concentration of 1.0 mg/mL 
of blood. The Fe3O4-MNPs/DNR were scrubbed with distilled 
water twice, lixiviated with saline, with a final   concentration 
reached of 100 mg/mL. Saline was used as the negative 
control and distilled water was used as the positive control. 
The materials detected were divided into three   concentration 
groups, ie, 100, 50, and 25 mg/mL. Each group had three 
test tubes, each tube containing 10 mL leaching liquor 
of   materials, saline, or distilled water, and preheated for 
30 minutes at 37°C. Then, 0.2 mL of diluted anticoagu-
lated blood was added to each tube. After incubation for 
60 minutes at 37°C, the process of hemolysis was observed 
macroscopically, the tubes were centrifugated at 2500 rpm 
for five minutes, the supernatant fluid was assembled, and 
optical density (OD) values were determined at 545 nm 
using ultraviolet-visible spectrophotometry. The hemoly-
sis rate was calculated using the mean OD value for each 
group as follows: hemolysis rate (%) = (mean of compound 
nanoparticles group - mean of negative control group)/
(mean of positive control group - mean of negative control 
group) × 100%. If the hemolysis rate was less than 5%, the 
material would have no hemolytic reaction, which fits the 
requirements of a hemolysis test.
Micronucleus assay
Experimental mice were randomly assigned to 10 groups; 
the Fe3O4-MNPs/DNR groups were divided into 1.25, 2.50, 
3.75, and 5.00 g/kg, the isodose DNR groups calculated using 
the effective drug-loading rate were set, the positive control 
group was injected intraperitoneally with cyclophosphamide 
100 mg/kg, and the negative control group was injected 
with an equivalent volume of saline. All experimental 
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between of 24 hours. After the second administration of the 
  experimental treatments, the animals were sacrificed.12,13 
Bone marrow slides were prepared, immobilized with 
  methanol for 15 minutes, and stained with Giemsa or DAPI 
for 15 minutes. At least 1000 polychromatic erythrocytes 
were counted for each mouse, and the rate of formation 
of polychromatic erythrocytes in the micronucleus was 
  calculated. Statistically significant differences were detected 
by Poisson distribution.
Determination of LD50
Experimental mice were randomly assigned to treatment 
groups containing 10 mice per group. The Fe3O4-MNPs/DNR 
suspension was injected intraperitoneally, with different 
dosing groups set at 0.1, 0.5, 0.9, 1.2, 1.6, and 2.0 g/kg. 
Isodose DNR control groups were determined by calculating 
the effective drug-loading rate. Saline was used as the 
negative control. All experimental animals were observed 
continuously for 15 days. Deaths of mice in each group were 
recorded, and the LD50 of the compound material and DNR 
was calculated by the Bliss method.
Acute toxicity test
Experimental mice were assigned randomly to three groups, 
with each group containing six mice. The mice allocated to 
receive Fe3O4-MNPs/DNR were injected intraperitoneally 
at a dose of 100 mg/kg (according to the therapeutic dose of 
DNR), whereas the control group was administered isodose 
DNR calculated by the effective drug-loading rate. The 
negative control group was given an equivalent volume of 
saline. Change in body weight for the mice was recorded 
at 24, 48, and 72 hours. General physical state, including 
respiration, eating and movement, was recorded, and adverse 
reactions were monitored over 14 days,14 after which serum 
alanine transaminase, blood urea nitrogen, and creatinine 
clearance were determined.
statistical analysis
Data were analyzed using the Statistical Package for Social 
Science (version 13.0; SPSS Inc., Chicago, IL). The statistical 
significance of differences in mean values between the groups 
was analyzed using one-way analysis of variance (ANOVA). 
P values ,0.05 were considered statistically significant.
Results
hemolysis testing
OD values at 545 nm are listed in Table 1 for each experimental 
group. Hemolysis rates at the different   concentrations of 
Fe3O4-MNPs/DNR were 2.908%, 2.530%, and 2.415%, 
respectively. The hemolysis rates for all three concentrations 
of Fe3O4-MNPs/DNR were less than 5%, which is considered 
to be the threshold for a hemolytic reaction.
Morphology from micronucleus assay
Femoral bone marrow morphology and micronucleus 
formation using Giemsa and DAPI staining were observed 
under an optical microscope and a fluorescence microscope, 
respectively (Figure 1). Micronucleus formation rates in 
femoral bone marrow at different doses of Fe3O4-MNPs/
DNR were not statistically different compared with either 
the negative control group (P . 0.05) or isodose DNR group 
(P . 0.05), but micronucleus formation rates at different 
doses of Fe3O4-MNPs/DNR, in the isodose DNR group, and 
in the negative control group, showed a significant difference 
compared with the positive control group (Table 2; P , 0.05), 
suggesting that Fe3O4-MNPs/DNR had no inherent toxicity 
to bone marrow cells in mice.
Table 1 hemolysis test of compound nanoparticles Fe3O4-MNPs/
DNr (n = 3, Mean ± sD)
Groups OD HR (%)
saline as negative control  0.0013 ± 0.002 –
100 mg/mL of compound nanoparticles   0.019 ± 0.004 2.908
50 mg/mL of compound nanoparticles  0.0167 ± 0.002 2.530
25 mg/mL of compound nanoparticles    0.016 ± 0.001 2.415
Distilled water as positive control    0.610 ± 0.015 –
Abbreviations: Fe3O4-MNPs, magnetic Fe3O4 nanoparticles; DNr, daunorubicin; 
OD, optical density; hr, hemolysis rate; sD, standard deviation.
Table  2  Micronucleus  test  of  magnetic  nanoparticles  Fe3O4-
MNPs/DNr
Groups MN formulation rate (‰)
saline as negative control  1.9c
1.25 g/kg of Fe3O4-MNPs/DNr  2.1a–c
2.5 g/kg of Fe3O4-MNPs/DNr 2.2a–c
3.75 g/kg of Fe3O4-MNPs/DNr 2.0a–c
5.0 g/kg of Fe3O4-MNPs/DNr 2.5a–c
12.5 mg/kg of DNr 2.4a,c
25.0 mg/kg of DNr 2.3a,c
37.5 mg/kg of DNr 2.6a,c
50.0 mg/kg of DNr 2.8a,c
100 mg/kg of cTX as positive control  26.7
Notes:  aP  .  0.05,  Magnetic  nanoparticles  Fe3O4-MNPs/DNr  groups  compared 
with negative control; bP . 0.05, magnetic nanoparticles Fe3O4-MNPs/DNr group 
compared with isodose DNr group; cP , 0.05, magnetic nanoparticles Fe3O4-MNPs/
DNr groups and isodose DNr groups compared with positive group.
Abbreviations: Fe3O4-MNPs, magnetic Fe3O4 nanoparticles; DNr, daunorubicin; 
MN, micronucleus; cTX, cyclophosphamid.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Determination of LD50
Mortality rates in the treatment groups were used to calculate 
the LD50 of Fe3O4-MNPs/DNR, which was 1009.71 mg/kg 
(relative concentration of DNR was 10 mg/kg according to 
the drug-loading rate), and its 95% confidence interval (CI) 
was 769.11–1262.40 mg/kg, while that of the DNR group 
was 8.51 mg/kg (95% CI: 6.48–10.37 mg/kg), indicating that 
Fe3O4-MNPs/DNR have a wide margin of safety.
Acute toxicity in mice
The body weights of mice treated with Fe3O4-MNPs/DNR, 
isodose DNR, or saline showed no significant difference at 
24, 48, and 72 hours (P . 0.05; Figure 2). During the 14-day 
observation period, all the mice remained in good condition, 
with normal consumption of water and food, and their stools 
were firm and yellowish-brown. Interestingly, toxic reactions, 
including instability of gait, convulsion, paralysis, and respira-
tory depression, were not observed during the study. Alanine 
transaminase, blood urea nitrogen, and creatinine clearance 
in the Fe3O4-MNPs/DNR groups were 66.0 ± 28.55 U/L, 
9.06 ± 1.05 mmol/L, and 18.03 ± 1.84 µmol/L, respectively 
(Figure 3). There was no significant difference compared 
with the negative control group and isodose DNR group 
(P . 0.05), suggesting that Fe3O4-MNPs/DNR did not have 
any acute general toxicity.
Discussion
Nanomaterials interact directly with tissues and cells after 
entering the body. Therefore, the most basic criteria for its 
clinical application are safety and good biocompatibility, 
which is also important to the industrialization of nano-
medicine. At present, evaluation of the biocompatibility of 
biomaterials is mainly carried out using in vitro and in vivo 
tests. The biocompatibility of magnetic nanoparticles is deter-
mined by their size and surface modifications. Some research-
ers have reported that Fe3O4-MNPs could be prepared into 
particles with satisfactory dispersion and biocompatibility.15 
Our earlier research showed that the concentrations of these 
nanoparticles in cells affected by hematologic malignancy 
were much higher than those in normal somatocytes, indi-
cating that this material has no overt toxicity to normal 
cells.5 However, findings from in vitro and vivo testing may 
be quite different because of differences in the number of 
cells used in such experiments. Thus, toxicologic testing and 
metabolic processes in vivo need further research. This work 
investigated the toxicity of self-assembled Fe3O4-MNPs/DNR 
through hemolysis testing, micronucleus assay, detection of 
LD50, and acute toxicity testing.
Hemolysis testing, which is a type of acute toxicity screen 
assay, was mainly used to evaluate the hemocompatibility of 
the materials when in contact with blood, and the aim was 
to detect hemolyzation of erythrocytes.16 This trial could 
sensitively reflect the influence of the nanoparticles on the 
erythrocyte membrane. Fe3O4-MNPs/DNR are mainly used 
for chemotherapy and thermotherapy, and may be in contact 
with blood directly or indirectly for a long time, so evaluation 
of their hemocompatibility is very important. Both mechanical 
injury induced by the material surface and the chemical action 
of soluble remnant molecules could cause abnormal quantity 
and quality of erythrocyte membrane proteins and lipids, 
resulting in destruction of erythrocyte membrane integrity and 
hemolyzation.17–19 The present paper shows that absorbance 
Figure 1 The result of the micronucleus test of magnetic nanoparticles Fe3O4-
MNPs/DNr.
Notes:  A1)  normal  bone  marrow  of  mice  observed  by  optical  microscope 
(giemsa staining, 10 × 100); B1) normal bone marrow of mice observed by optical 
microscope (DAPI staining, 10 × 100); A2) formation of micronucleus observed 
through fluorescence microscope (Giemsa staining, 10 × 100); B2) formation of 
micronucleus observed through fluorescence microscope (DAPI staining, 10 × 100) 
(Formation of micronucleus are indicated by “→”).
Abbreviations: Fe3O4-MNPs, magnetic Fe3O4 nanoparticles; DNr, daunorubicin; 
DAPI, 4,6-diamidino-2-phenylindole.
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of free hemoglobin, released by   materials in contact with 
hemocytes in vitro, could be detected using ultraviolet spectro-
photometry20 in order to calculate the extent of hemolysis. The 
hemolyzation rate of these nanoparticles at different concen-
trations was less than 5%, indicating that Fe3O4-MNPs/DNR 
do not cause hemolysis and have good hemocompatibility. 
Further evaluation of the inherent toxicity and carcinogenicity 
of such biomaterials has been recommended,21 so we chose a 
micronucleus assay to evaluate the inherent toxicity of Fe3O4-
MNPs/DNR. We found no statistically significant difference 
in micronucleus formation rates at different doses of Fe3O4-
MNPs/DNR compared with the negative control group, but 
there was a significant difference compared with the positive 
control group. Thus we can infer that these nanoparticles do 
not induce abnormalities or mutations.
The acute general toxicity test is used to evaluate short-
term toxicity after intraperitoneal administration. In cancer 
therapy, optimized dosing is crucial not only for inhibiting 
tumor growth or even promoting apoptosis of tumor cells, 
but also for preventing the tumor from developing drug 
resistance and contributing to relapse.22 The development of 
highly biocompatible, nontoxic nanoparticles is necessary. 
The LD50 of Fe3O4-MNPs/DNR was 1009.71 mg/kg, and 
the relative concentration of DNR was 10 mg/kg according 
to the drug-loading rate, which was much higher than that 
of therapeutic doses of DNR in mice, suggesting that these 
nanoparticles have a wide safety margin. Furthermore, it was 
investigated whether nanoparticles could cause long-term 
changes in systemic activity, liver function, or renal function. 
Certain characteristics of nanoparticles, including surface 
features, size, and shape, can affect particle–cell interactions 
and interactions with serum proteins.23 Previous research has 
reported that uptake of the major fraction of injected dextran-
coated iron oxide MNPs is by Küpffer cells.24 Other studies 
have revealed that more than 75% uptake of MNPs occurs 
in the reticuloendothelial system, particularly in the liver.25 
It has also been suggested that Küpffer cells in the liver can 
degrade iron oxide MNPs and can incorporate most of the 
iron into ferritin.26 In our study, we monitored for systemic 
toxic reactions after intraperitoneal administration of Fe3O4-
MNPs/DNR for 14 days. None of the experimental animals 
showed any signs of instability, and indices of liver and renal 
function, such as alanine transaminase, blood urea nitrogen, 
and creatinine clearance, were within the normal range. Thus, 
we can assume that these nanoparticles did not cause any 
short-term systemic changes.
Conclusion
Fe3O4-MNPs/DNR had good biocompatibility in mice 
according to this short-term evaluation of toxicity and may be 
useful for targeted tumor therapy and could replace congener 
chemotherapeutics in clinical therapy in the future.
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